141 related articles for article (PubMed ID: 2305716)
21. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
22. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporine in the treatment of cutaneous T cell lymphoma.
Street ML; Muller SA; Pittelkow MR
J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1084-9. PubMed ID: 2273106
[TBL] [Abstract][Full Text] [Related]
24. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
Kessler JF; Jones SE; Levine N; Lynch PJ; Booth AR; Meyskens FL
Arch Dermatol; 1987 Feb; 123(2):201-4. PubMed ID: 2949706
[TBL] [Abstract][Full Text] [Related]
25. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
Cox EB; Vogel CL; Carpenter JT; Raney M
Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
[TBL] [Abstract][Full Text] [Related]
26. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy SA
Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
[TBL] [Abstract][Full Text] [Related]
27. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of teniposide in patients with ovarian cancer.
D'Incalci M; Rossi C; Sessa C; Urso R; Zucchetti M; Farina P; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):73-7. PubMed ID: 3967261
[TBL] [Abstract][Full Text] [Related]
29. Teniposide is not effective in chronic lymphocytic leukemia.
Zagonel V; Tirelli U; Veronesi A; Galligioni E; Tumolo S; Roncadin M; Carbone A; Grigoletto E
Blut; 1986 Jan; 52(1):59-61. PubMed ID: 3632912
[TBL] [Abstract][Full Text] [Related]
30. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
Querfeld C; Zain J; Rosen ST
Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
[TBL] [Abstract][Full Text] [Related]
31. A phase II study with teniposide (VM26) in patients with progressed or relapsed small cell lung cancer (SCLC).
Tummarello D; Guidi F; Di Furia L; Gramazio A; Menichetti E; Cellerino R
J Chemother; 1989 Feb; 1(1):64-7. PubMed ID: 2542470
[TBL] [Abstract][Full Text] [Related]
32. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
33. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
34. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
[TBL] [Abstract][Full Text] [Related]
35. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
[TBL] [Abstract][Full Text] [Related]
36. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
38. VM26: phase I and II studies.
Macbeth FR
Cancer Chemother Pharmacol; 1982; 7(2-3):87-91. PubMed ID: 7044595
[No Abstract] [Full Text] [Related]
39. [Diagnosis and therapy of cutaneous T-cell lymphomas].
Le T; Pierard GE; Pierard-Franchimont C; de la Brassinne M; Lapière CM
Dermatologica; 1984; 169(2):60-5. PubMed ID: 6332749
[TBL] [Abstract][Full Text] [Related]
40. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]